20 Most Expensive Stocks Insiders Are Dumping In March

9. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Market Capitalization: $130.72 billion

Vertex Pharmaceuticals is a biotechnology company focused on developing therapies for cystic fibrosis (CF) and other diseases. It markets several CF treatments, including TRIKAFTA/KAFTRIO, ALYFTREK, and ORKAMBI, and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions. The Boston, Massachusetts-based company collaborates with CRISPR Therapeutics, Moderna, and Entrada Therapeutics, and sells its products through specialty pharmacies and distributors.

For the full year 2024, Vertex disclosed product revenue of $11.02 billion, up 12% year-over-year. The revenue growth was primarily driven by the continued performance of TRIKAFTA/KAFTRIO. Net product revenue increased 11% to $4.34 billion outside the U.S. on strong patient demand in both established and newer markets. GAAP net loss and non-GAAP net income were $536 million and $111 million, respectively, compared to GAAP net income of $3.6 billion and non-GAAP net income of $4.0 billion, respectively, for 2023.

For the full year 2025, Vertex projects revenue to be in the range of $11.75 billion to $12 billion.

In recent developments, Vertex announced that the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) has granted approval for ALYFTREK, a once-daily treatment for cystic fibrosis. It is for people aged 6 and older with at least one F508del mutation or another responsive mutation in the CFTR gene.

In March, three insiders, including the CSO and CFO sold approximately $10.09 million worth of Vertex Pharmaceuticals shares at an average price of $497.58 per share. Year-to-date, the stock is up 26.41%, trading at $509.04 per share. Over the past 12 months, its shares returned 21.65%.

Twenty-six analysts rate Vertex as “Moderate Buy” with a price target of $506.70 per share, according to MarketBeat. The average price target suggests a downside of 0.46% from the latest price.

Read here what Mad Money host Jim Cramer recently said about Vertex stock.